innoscripta SE, a provider of a scalable software platform for managing R&D activities, announced a robust first half of 2026, with revenue climbing 43% year-over-year to EUR 63.1 million. Adjusted EBIT increased by 49% to EUR 36.4 million, reflecting the company's efficient operational model and the growing demand for its Clusterix platform.
The company's growth was fueled by the German R&D tax allowance (Forschungszulage), which remains a key driver. The number of customers using Clusterix to structure projects and manage applications surpassed 2,900 during the period. Clusterix has been further enhanced as the central infrastructure, enabling automated data validation, higher data quality, and standardized workflows across different markets. This technological foundation is critical for innoscripta's international scaling efforts.
International expansion progressed as planned, with successful entries into France, the UK, and the US. In France, a new office near Toulouse has already secured customers. The UK market entry via a Manchester location became operational on July 1, 2026, and the US market is being served with initial contracts signed. The flexibility of Clusterix in adapting to various regulatory environments allows the company to enter new markets efficiently.
Management confirmed the guidance for the full year 2026, expecting revenue of at least EUR 140 million and EBIT of at least EUR 80 million, assuming consistent timing of customer applications. Detailed financials are available in the Half-Year Report on the company's website.
innoscripta's performance underscores the increasing importance of digital solutions for R&D management and the company's successful execution of its growth strategy. The expansion into new geographies and the strengthening of its platform position it well for continued success.
